Postdoctoral fellow in asthma research. NIH-funded project studies the mechanisms of a novel therapy for allergic airway inflammation that involves β2AR function in airway epithelium and the participation of IL-13 and STAT6. Genetically modified mice are treated with beta-blockers and assessed for allergen sensitization, mucous metaplasia airway resistance. Studies are also aimed at elucidating the effects of beta-blockers on signal transduction in airway epithelium. See Am. J. Resp. Cell Molec. Biol. 38:256 (2008) and Proc. Natl. Acad. Sci. U.S.A. 106:2435 (2009). The laboratory is based at the University of Houston College of Pharmacy and collaborates with groups located at the Texas Medical Center, MD Anderson Cancer Center and Baylor College of Medicine. A Ph.D. and experience in working with transgenic animals is required. Experience with pharmacology, biochemistry, molecular biology, or airway biology is desirable. Send a CV and contact information for 3 references to Richard A. Bond, Ph.D. (rabond@uh.edu), Dept. of Pharmacological and Pharmaceutical Sciences, University of Houston, Rm 542 SR2, 77204-5037.
The University of Houston is an Affirmative Action/ Equal Employment Opportunity. Minorities, women, veterans and persons with disabilities are encouraged to apply.
A resume is required to apply to this job. Applications are sent to the employer via e-mail. Before you can apply, you will be asked to sign in to your Science Careers account or to create a new account. Please click on the link below and follow instructions.
